Pharmacogenomics

Papers
(The H4-Index of Pharmacogenomics is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience39
Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?31
Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment27
Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy25
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry25
Assessment of primary care practitioners’ attitudes and interest in pharmacogenomic testing22
The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis22
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention21
The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review21
PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing21
Potential of whole-genome sequencing-based pharmacogenetic profiling18
Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study18
Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective18
Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors17
Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs17
PGxKnow: a pharmacogenomics educational HoloLens application of augmented reality and artificial intelligence16
Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program16
Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly16
0.042622089385986